EUVIMEDEUVIMED entdecken
Open Access

Palmitoylation of NLRP3 Modulates Inflammasome Activation and Inflammatory Bowel Disease Development

Dingwen Hu, Yuting Li, Xianyang Wang, Haimei Zou, Zonghui Li, Weijie Chen, Yu Meng, Yingchong Wang, Qin Li, Feng Liao, Kailang Wu iD, Jianguo Wu und 2 weitere

The Journal of Immunology · 15.08.2024 · 213 (4) · 481-493

DOI: 10.4049/jimmunol.2300241 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Immunology, online erschienen am 01.07.2024. Verfasst von Dingwen Hu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Experimental Center, Jiangmen Central Hospital, Jiangmen, China. Hauptthemen laut MEDLINE: NLR Family, Pyrin Domain-Containing 3 Protein, Inflammasomes, Lipoylation, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Guangdong academy of medical science, National nature science foundation of China, Key-Area Research and Development Program of Guangdong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aberrant activity of NLRP3 has been shown associations with severe diseases. Palmitoylation is a kind of protein post-translational modification, which has been shown to regulate cancer development and the innate immune system. Here, we showed that NLRP3 is palmitoylated at Cys419 and that palmitoyltransferase ZDHHC17 is the predominant enzyme that mediates NLRP3 palmitoylation and promotes NLRP3 activation by interacting with NLRP3 and facilitating NIMA-related kinase 7 (NEK7)–NLRP3 interactions. Blockade of NLRP3 palmitoylation by a palmitoylation inhibitor, 2-bromopalmitate, effectively inhibited NLRP3 activation in vitro. Also, in a dextran sulfate sodium–induced colitis model in mice, 2-bromopalmitate application could attenuate weight loss, improve the survival rate, and rescue pathological changes in the colon of mice. Overall, our study reveals that palmitoylation of NLPR3 modulates inflammasome activation and inflammatory bowel disease development. We propose that drugs targeting NLRP3 palmitoylation could be promising candidates in the treatment of NLRP3-mediated inflammatory diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NLR Family, Pyrin Domain-Containing 3 ProteinInflammasomesLipoylationInflammatory Bowel DiseasesAcyltransferasesColitisAnimalsMiceHumansDextran SulfateMice, Inbred C57BLNIMA-Related KinasesPalmitatesDisease Models, AnimalHEK293 CellsProtein Processing, Post-Translational

Substanzen

NLR Family, Pyrin Domain-Containing 3 ProteinInflammasomesAcyltransferasesNlrp3 protein, mouseDextran SulfateNIMA-Related KinasesPalmitatesNek7 protein, mouse2-bromopalmitate

Autor:innen und Institutionen

  • Clinical Experimental Center, Jiangmen Central Hospital, Jiangmen, China.
  • State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan, China.
  • Laboratory Animal Center, Guangzhou University of Chinese Medicine, Guangzhou, China.
  • Guangdong Provincial Key Laboratory of Virology, Institute of Medical Microbiology, Jinan University, Guangzhou, China.
  • Medical Research Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.

ORCID-Profile: Kailang Wu

Förderung

  • Guangdong academy of medical science
  • National nature science foundation of China
  • Key-Area Research and Development Program of Guangdong Province
  • Guangzhou University of Chinese Medicine First-class universities and Top Disciplines Scientific Research Team Projects

Zitieren

APA

Hu, D., Li, Y., Wang, X., Zou, H., Li, Z., Chen, W., Meng, Y., Wang, Y., Li, Q., Liao, F., Wu, K., Wu, J., Li, G., & Wang, W. (2024). Palmitoylation of NLRP3 Modulates Inflammasome Activation and Inflammatory Bowel Disease Development. The Journal of Immunology, 213(4), 481-493. https://doi.org/10.4049/jimmunol.2300241

Vancouver

Hu D, Li Y, Wang X, Zou H, Li Z, Chen W, et al. Palmitoylation of NLRP3 Modulates Inflammasome Activation and Inflammatory Bowel Disease Development. The Journal of Immunology. 2024;213(4):481-493. doi:10.4049/jimmunol.2300241

BibTeX
@article{Hu2024,
  author = {Hu, Dingwen and Li, Yuting and Wang, Xianyang and Zou, Haimei and Li, Zonghui and Chen, Weijie and Meng, Yu and Wang, Yingchong and Li, Qin and Liao, Feng and Wu, Kailang and Wu, Jianguo and Li, Geng and Wang, Wenbiao},
  title = {Palmitoylation of NLRP3 Modulates Inflammasome Activation and Inflammatory Bowel Disease Development},
  journal = {The Journal of Immunology},
  year = {2024},
  volume = {213},
  number = {4},
  pages = {481--493},
  doi = {10.4049/jimmunol.2300241}
}
Kostenlos starten →